321 related articles for article (PubMed ID: 26886346)
1. Acetate- and Citrate-Specific Ion Effects on Unfolding and Temperature-Dependent Aggregation Rates of Anti-Streptavidin IgG1.
Barnett GV; Razinkov VI; Kerwin BA; Hillsley A; Roberts CJ
J Pharm Sci; 2016 Mar; 105(3):1066-73. PubMed ID: 26886346
[TBL] [Abstract][Full Text] [Related]
2. Specific-ion effects on the aggregation mechanisms and protein-protein interactions for anti-streptavidin immunoglobulin gamma-1.
Barnett GV; Razinkov VI; Kerwin BA; Laue TM; Woodka AH; Butler PD; Perevozchikova T; Roberts CJ
J Phys Chem B; 2015 May; 119(18):5793-804. PubMed ID: 25885209
[TBL] [Abstract][Full Text] [Related]
3. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.
Roberts CJ; Nesta DP; Kim N
J Pharm Sci; 2013 Oct; 102(10):3556-66. PubMed ID: 23873602
[TBL] [Abstract][Full Text] [Related]
4. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
Brummitt RK; Nesta DP; Roberts CJ
J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
[TBL] [Abstract][Full Text] [Related]
5. Effects of Protein Conformation, Apparent Solubility, and Protein-Protein Interactions on the Rates and Mechanisms of Aggregation for an IgG1Monoclonal Antibody.
Kalonia C; Toprani V; Toth R; Wahome N; Gabel I; Middaugh CR; Volkin DB
J Phys Chem B; 2016 Jul; 120(29):7062-75. PubMed ID: 27380437
[TBL] [Abstract][Full Text] [Related]
6. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
7. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration.
Kim N; Remmele RL; Liu D; Razinkov VI; Fernandez EJ; Roberts CJ
Biophys Chem; 2013 Feb; 172():26-36. PubMed ID: 23334430
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
9. Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies.
Thakkar SV; Joshi SB; Jones ME; Sathish HA; Bishop SM; Volkin DB; Middaugh CR
J Pharm Sci; 2012 Sep; 101(9):3062-77. PubMed ID: 22581714
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species.
Zheng S; Qiu D; Adams M; Li J; Mantri RV; Gandhi R
AAPS PharmSciTech; 2017 Jan; 18(1):42-48. PubMed ID: 26340951
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies.
Sahin E; Grillo AO; Perkins MD; Roberts CJ
J Pharm Sci; 2010 Dec; 99(12):4830-48. PubMed ID: 20821389
[TBL] [Abstract][Full Text] [Related]
12. Molecular Computations of Preferential Interaction Coefficients of IgG1 Monoclonal Antibodies with Sorbitol, Sucrose, and Trehalose and the Impact of These Excipients on Aggregation and Viscosity.
Cloutier T; Sudrik C; Mody N; Sathish HA; Trout BL
Mol Pharm; 2019 Aug; 16(8):3657-3664. PubMed ID: 31276620
[TBL] [Abstract][Full Text] [Related]
13. High throughput thermostability screening of monoclonal antibody formulations.
He F; Hogan S; Latypov RF; Narhi LO; Razinkov VI
J Pharm Sci; 2010 Apr; 99(4):1707-20. PubMed ID: 19780136
[TBL] [Abstract][Full Text] [Related]
14. The effect of arginine glutamate on the stability of monoclonal antibodies in solution.
Kheddo P; Tracka M; Armer J; Dearman RJ; Uddin S; van der Walle CF; Golovanov AP
Int J Pharm; 2014 Oct; 473(1-2):126-33. PubMed ID: 24992318
[TBL] [Abstract][Full Text] [Related]
15. Effect of buffer species on the unfolding and the aggregation of humanized IgG.
Kameoka D; Masuzaki E; Ueda T; Imoto T
J Biochem; 2007 Sep; 142(3):383-91. PubMed ID: 17646171
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association.
Sudrik CM; Cloutier T; Mody N; Sathish HA; Trout BL
Pharm Res; 2019 May; 36(8):109. PubMed ID: 31127417
[TBL] [Abstract][Full Text] [Related]
17. Sorbitol crystallization-induced aggregation in frozen mAb formulations.
Piedmonte DM; Hair A; Baker P; Brych L; Nagapudi K; Lin H; Cao W; Hershenson S; Ratnaswamy G
J Pharm Sci; 2015 Feb; 104(2):686-97. PubMed ID: 25219372
[TBL] [Abstract][Full Text] [Related]
18. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
19. Nano Differential Scanning Fluorimetry-Based Thermal Stability Screening and Optimal Buffer Selection for Immunoglobulin G.
Kim SH; Yoo HJ; Park EJ; Na DH
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056086
[TBL] [Abstract][Full Text] [Related]
20. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.
Brummitt RK; Nesta DP; Chang L; Chase SF; Laue TM; Roberts CJ
J Pharm Sci; 2011 Jun; 100(6):2087-103. PubMed ID: 21213308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
